Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

Share this content:
Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion
Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

ORLANDO, FLIn “ultra-high risk” patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring 17p deletion, treatment with venetoclax monotherapy resulted in a high overall response rate and sustained remissions, a pivotal international phase 2 study reported at the 57th American Society of Hematology (ASH) Annual Meeting.1

“Venetoclax may provide an attractive treatment option for 17p deletion CLL as monotherapy or in the future as a component of novel combination strategies,” said Stephan Stilgenbauer, MD, PhD, of University of Ulm in Germany.

Previously, a first-in-human study showed an overall response rate of 79% for venetoclax in patients with relapsed/refractory CLL, including del(17p), considered to be a population with a very poor prognosis.

In this study, venetoclax, an “orally bioavailable, selective BCL-2 inhibitor that induces apoptosis in CLL cells independent of p53,” was evaluated as monotherapy in 107 patients. Venetoclax was administered once daily, with a weekly dose ramp-up schedule of 20 mg (test), 50 mg, 100 mg, 200 mg, and 400 mg over 5 weeks, with risk-based prophylaxis to mitigate tumor lysis syndrome.

Median age was 67 years (range, 37-85) and 65% were male. The majority of patients (72.9%) had received prior fludarabine and bendamustine, with half refractory to therapy; the median number of prior regimens was 2 (range, 1-10). Only 1 patient did not have a 17p deletion, and investigators reported 60 of 83 patients (72.3%) with available data had a TP53 mutation.

As of April 30, 2015, median time on study was 12.1 months (range, 0.03-21.5).

The primary end point, independent review committee-assessed overall response rate, was 79.4% (95% CI: 70.5-86.6). Deep responses included 8 (7.5%) complete remission (CR)/CR with incomplete platelet recovery (CRi) and 3 (2.8%), near partial remission (nPR).

A total of 74 patients achieved PR (69.2%, excluding nPR) and 22 did not respond to treatment (20.6%). Of 48 patients, 25 had no CLL in the bone marrow,  Dr. Stilgenbauer reported.

A total of 45 patients were assessed for minimal residual disease (MRD) and 18 (17% of entire cohort, 21% of those who responded to treatment) had no detectable MRD in peripheral blood.

Median time-to-first response was 0.8 months (range, 0.1-8.1), and median time to CR/CRi was 8.2 months (range, 3.0-16.3). Overall median duration of response, progression-free survival, and overall survival were not reached. The actuarial 12-month rate for progression-free survival was 72.0% and the overall survival rate was 86.7%. For duration of response, the 12-month rate was 84.7% among the 85 responders; 100% for the 11 patients defined as being deep responders (CR, CRi, nPR), 82.6% for the 74 patients in partial remission, and 94.4% for the 18 patients who were MRD-negative.

Treatment-emergent adverse events (all grades) included neutropenia (43%), diarrhea (29%), nausea (29%), anemia (27%), and fatigue (22%); 22.4% of patients had baseline neutropenia. Serious adverse events occurred in 55% of patients; the most common was pyrexia in 7%, autoimmune hemolytic anemia in 7%, pneumonia in 6%, and febrile neutropenia in 5%.

The incidence of neutropenia and infection are similar to that observed with other frontline chemoimmunotherapy regimens, he said.

Laboratory tumor lysis syndrome was reported in five patients during the ramp-up period; “none had clinical consequences, and all were manageable with electrolyte management and 1-day dose interruption” in 2 patients, Dr Stilgenbauer reported.


1. Stilgenbauer S, Eichhorst BF, Schetelig J, et al. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p Deletion: results of the pivotal international phase 2 study. Oral presentation at: 57th American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2015; Orlando, FL.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs